A Phase 1/2 interventional study of CL20-i4-EF1α-hγc-OPT and Busulfan in Severe Combined Immunodeficiency Disease, X-linked, sponsored by St. Jude Children's Research Hospital. Suspended at 3 sites in United States. Open to male participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by St. Jude Children's Research Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. X-Linked Combined Immunodeficiency Diseases · United States.
Among the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 1/2, and was the 14th registered.
28 studies on the registry are indexed under X-Linked Combined Immunodeficiency Diseases; 9 are open to participants now.
Browse X-Linked Combined Immunodeficiency Diseases studies →5 of the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:
David Williams · Sites in United States
Ages 0–5 · Men only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–50 · Men only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3–99 · Men only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Canada
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 X-Linked Combined Immunodeficiency Diseases studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: Up to 24 Months · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 8
First in 1997; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is above the median of 9 across 16 interventional studies indexed under X-Linked Combined Immunodeficiency Diseases.
Median enrollment 12 across the 11 interventional studies, 478 across the 8 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 20 have an industry lead sponsor. The 10 most frequent:
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
St. Jude Children's Research Hospital has 1 study filed under X-Linked Combined Immunodeficiency Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in X-Linked Combined Immunodeficiency Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SCID-X1 is a genetic disorder of blood cells caused by DNA changes in a gene that is required for the normal development of the human immune system. The purpose of this study is to determine if a new method, called lentiviral gene transfer, can be used to treat SCID-X1. This method involves transferring a normal copy of the common gamma chain gene into the participant's bone marrow stem cells. The investigators want to determine if the procedure is safe, whether it can be done according to the methods they have developed, and whether the procedure will provide a normal immune system for the patient. It is hoped that this type of gene transfer may offer a new way to treat children with SCID-X1 that do not have a brother or sister who can be used as a donor for stem cell transplantation.
Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the γc gene, and reinfused without any myeloreductive conditioning. Participants will be monitored for hematopoietic recovery from busulfan and for severe adverse events for 42 days post gene therapy. The primary endpoint assessing the efficacy of this approach will be T-cell immune reconstitution 52 weeks (± 4) weeks after transplantation. Continued and detailed evaluation of all aspects of immune reconstitution, protocol-related toxicity, and retroviral integration sites will also be performed. This study will evaluate the first use of a SIN lentiviral vector for the treatment of SCID-X1 and may lead to a new form of therapy that could be applied to the majority of newly diagnosed patients.
OBJECTIVES
Assess the safety, feasibility and efficacy of lentiviral gene transfer in newly diagnosed SCID-X1 patients transplanted with autologous CD34+ cells that have been transduced with a self-inactivating lentiviral vector (CL20-i4-EF1α-hγc-OPT) expressing a γc gene.
Primary Objective 1: Evaluate the safety and feasibility of infusing at least 1 million transduced CD34+ cells per kilogram of body weight in SCID-X1 infants.
Primary Objective 2: Evaluate the efficacy of lentiviral gene transfer for inducing significant T-cell reconstitution 52 weeks (± 4 weeks) after transplantation. Significant reconstitution of T cells is defined as at least 2 of the following 3 criteria being present:
OTHER PRE-SPECIFIED OBJECTIVES:
Inclusion Criteria:
* Treatment Eligibility Criteria:
Treatment Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-i4-EF1α-hγc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1α-hγc-OPT
Genetic: CL20-i4-EF1α-hγc-OPT · Drug: Busulfan · Device: CliniMacs
Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
Also known as: self inactivating lentiviral vector, IND 14570
Given intravenously (IV).
Also known as: Busulfex®, Myleran®
Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
Number of patients with adequate cell collection and processing
The number of patients who underwent no more than two bone marrow harvests and cryopreservation of at least 1.0 million cells/kg following vector transduction.
Time frame: Day 0
Number of patients with adequate neutrophil count recovery after busulfan conditioning
Adequate recovery is defined as absolute neutrophil count (ANC) \>500 cells/μl by day +42 unless the patient is neutropenic prior to busulfan administration.
Time frame: Day 42 post gene transfer
Number of patients without Grade 4 adverse event (AE)
The number of patients experiencing no directly related grade 4 or greater adverse event.
Time frame: 42 days post gene transfer
Number of patients with successful reconstitution
Reconstitution with transduced cells defined as detection of vector-marked peripheral blood cells by real time PCR at or above 0.02% VCN in total WBC.
Time frame: 42 days post gene transfer
Number of patients with treatment failure
Treatment failure will be defined as lack of adequate cell collection and processing, lack of neutrophil count recovery by day +42, occurrence of grade 4 or greater toxicities by day +42, and/or lack of detection of \>0.02% transduced cells in peripheral blood by day +42 post gene transfer.
Time frame: 42 days post gene transfer
Pharmacokinetic (PK) variables of busulfan
Blood collections for pharmacokinetic sampling will be performed with dose 1 and used to determine dose modifications for dose 2, if needed. The specific times for blood collects will be institution specific. Summary statistics will be reported.
Time frame: Days -2 and -1 prior to therapy
Number of patients who achieve the desired therapeutic busulfan AUC
The efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan AUC of 22 mg\*hr/L will be evaluated. The number of patients who achieve the desired therapeutic busulfan AUC will be reported
Time frame: Day 0
B-cell function evaluated by Immune response
Evaluation may include γc expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG. Summary statistics will be reported.
Time frame: 52 weeks post gene transfer
Number of NK cells
Evaluation will include flow cytometry evaluation of NK cell numbers. Summary statistics will be reported.
Time frame: 52 weeks post gene transfer
Vector copy number by location of vector-integration sites in sorted blood cells
Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites. Summary statistics will be reported.
Time frame: up to 10 years post gene transfer
Event-free survival (EFS)
Event is defined as death, requiring boost post infusion, or an oncogenic event . EFS is defined as time from busulfan infusion to event defined here with all patients surviving at the time of analysis censored.
Time frame: from baseline up to 10 years post gene transfer
Overall survival (OS)
OS is defined as time from busulfan infusion to death with all patients surviving at the time of analysis censored.
Time frame: up to 10 years post gene transfer
Started Aug 2016 (actual). Primary completion is estimated for Oct 2027, 134 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Oct 2027 and completion Aug 2034 → Oct 2039.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Busulfan
X-Linked Combined Immunodeficiency Diseases →
St. Jude Children's Research Hospital →